These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 23459571

  • 1. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort.
    Olsson T, Achiron A, Alfredsson L, Berger T, Brassat D, Chan A, Comi G, Eraksoy M, Hegen H, Hillert J, Jensen PE, Moiola L, Myhr KM, Oturai A, Schippling S, Siva A, Sorensen PS, Trampe AK, Weber T, Potts J, Plavina T, Paes D, Subramanyam M, Wiendl H, Dib H, Uren D, Hemmer B, Buck D.
    Mult Scler; 2013 Oct; 19(11):1533-8. PubMed ID: 23459571
    [Abstract] [Full Text] [Related]

  • 2. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
    Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, Goelz S, Ziegler A, Gold R, Chan A.
    Neurology; 2012 May 29; 78(22):1736-42. PubMed ID: 22592369
    [Abstract] [Full Text] [Related]

  • 3. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1.
    Bozic C, Richman S, Plavina T, Natarajan A, Scanlon JV, Subramanyam M, Sandrock A, Bloomgren G.
    Ann Neurol; 2011 Nov 29; 70(5):742-50. PubMed ID: 22162056
    [Abstract] [Full Text] [Related]

  • 4. Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial.
    Bozic C, Subramanyam M, Richman S, Plavina T, Zhang A, Ticho B.
    Eur J Neurol; 2014 Feb 29; 21(2):299-304. PubMed ID: 24894998
    [Abstract] [Full Text] [Related]

  • 5. Anti-JC-virus antibody prevalence in a German MS cohort.
    Warnke C, Dehmel T, Posevitz-Fejfár A, Chan A, Berthele A, Schmidt S, Haas J, Kronsbein HC, Seitz F, Tackenberg B, Mäurer M, Gerbershagen K, Limmroth V, Adams O, Hartung HP, Gold R, Hemmer B, Wiendl H, Kieseier BC.
    Mult Scler; 2012 Jul 29; 18(7):1054-5. PubMed ID: 22740609
    [No Abstract] [Full Text] [Related]

  • 6. Anti-JC virus antibody sera positivity and index value among patients with multiple sclerosis may be correlated with age, sex, and area of residence.
    Koolaji S, Allahabadi NS, Ahmadi A, Eskandarieh S, Moghadasi AN, Azimi AR, Sahraian MA.
    J Neurovirol; 2018 Oct 29; 24(5):570-576. PubMed ID: 29785581
    [Abstract] [Full Text] [Related]

  • 7. JCV epidemiology in MS (JEMS)--epidemiology of anti-JCV antibody prevalence in multiple sclerosis patients--Portuguese data.
    da Silva AM, Santos ME, Portuguese JEMS Study Investigators.
    J Neurol Sci; 2014 Feb 15; 337(1-2):119-22. PubMed ID: 24369270
    [Abstract] [Full Text] [Related]

  • 8. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M, Plavina T, Khatri BO, Fox RJ, Goelz SE.
    Mult Scler; 2013 Jun 15; 19(7):912-9. PubMed ID: 23232602
    [Abstract] [Full Text] [Related]

  • 9. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 10. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
    Lee P, Plavina T, Castro A, Berman M, Jaiswal D, Rivas S, Schlain B, Subramanyam M.
    J Clin Virol; 2013 Jun 17; 57(2):141-6. PubMed ID: 23465394
    [Abstract] [Full Text] [Related]

  • 11. Anti-JC virus antibody titres increase over time with natalizumab treatment.
    Raffel J, Gafson AR, Malik O, Nicholas R.
    Mult Scler; 2015 Dec 17; 21(14):1833-8. PubMed ID: 26449743
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.
    Dominguez-Mozo MI, Rus M, Santiago JL, Izquierdo G, Casanova I, Galan V, Garcia-Martinez MA, Arias-Leal AM, García-Montojo M, Pérez-Pérez S, Arroyo R, Alvarez-Lafuente R.
    Eur J Clin Invest; 2017 Feb 17; 47(2):158-166. PubMed ID: 28036121
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Correlation between anti-JC-virus and anti-cytomegalovirus, -Epstein-Barr virus and -measles/-rubella/-varicella-zoster-virus antibodies.
    Auer M, Borena W, Holm-von Laer D, Deisenhammer F.
    J Med Virol; 2017 Jan 17; 89(1):3-9. PubMed ID: 27253624
    [Abstract] [Full Text] [Related]

  • 18. JC virus antibody status in a pediatric multiple sclerosis cohort: prevalence, conversion rate and influence on disease severity.
    Huppke P, Hummel H, Ellenberger D, Pfeifenbring S, Stark W, Huppke B, Brück W, Gärtner J.
    Mult Scler; 2015 Apr 17; 21(4):382-7. PubMed ID: 25070674
    [Abstract] [Full Text] [Related]

  • 19. Anti-JC Virus Antibody Prevalence in Canadian MS Patients.
    Bhan V, Lapierre Y, Freedman MS, Duquette P, Selchen D, Migounov V, Walt L, Zhang A.
    Can J Neurol Sci; 2014 Nov 17; 41(6):748-52. PubMed ID: 25377521
    [Abstract] [Full Text] [Related]

  • 20. Natalizumab therapy is associated with changes in serum JC virus antibody indices over time.
    Peters J, Williamson E.
    J Neurol; 2017 Dec 17; 264(12):2409-2412. PubMed ID: 29034436
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.